Skip to content
15% off your first order15% off your first order

CJC-1295 (no DAC) 10 mg vial

Also known as Modified GRF 1-29

Growth hormone release

Investigated for pulsatile growth hormone release.

$119.00CAD· $11.90/mg
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Needles and wipes are free. Water is $19.

Compare. Side by side, from the research.

About CJC-1295 (no DAC)

CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone analog with a short half-life, studied specifically for preserving the body's natural pulsatile release pattern.

How it works

GHRH Pathway
Studied as a releasing-hormone analog acting on the pituitary receptors that govern natural hormone pulses.
Short Half-Life
Without DAC its action is brief, which research associates with preserving the body's own pulsatile rhythm.
Read the full research

What you need

  • Bacteriostatic Water
  • Needles
  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Lyophilised powder in a sealed vial
Strength
10 mg per vial
Storage
Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
Reconstitution
2 mL bacteriostatic water for this 10 mg vial (5 mg/mL)
Route in research
Subcutaneous
Target
GHRH-R
SKU
CND10

Handling

  1. 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
  2. 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
  3. 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Early clinical

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

Early clinicalPublished human data consist of small clinical studies, including a randomized controlled trial of the long-acting DAC form of CJC-1295 in healthy adults, while the no-DAC form (modified GRF 1-29) appears mainly in reviews and anti-doping detection research.

What research examines

  • Growth hormone release through GHRH receptor signaling
  • Preservation of natural pulsatile growth hormone release
  • GH and IGF-I secretion in healthy adults (long-acting DAC form)
  • Discussion in sports medicine and orthopaedic peptide reviews
  • Discussion in healthy-aging peptide reviews
  • Analytical detection of GHRH analogs in anti-doping testing

Reported in studies

  • Human safety data specific to the no-DAC form are limited
  • Adverse events are not summarized in the cited titles
  • Reviews discuss safety questions around unapproved peptide therapies
  • GHRH synthetic analogs are targeted by anti-doping detection methods and have been identified in seized doping material
Read the full research page· 5 cited studies

Published research protocols

250 mcg, 5 days on 2 days off, pre-sleep fasted

Research protocols have used 100–300 mcg per administration, 5 days per week (pre-sleep), in 12-week blocks with 4 weeks off.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

Measure with the calculator

CoreX AI

Ask about CJC-1295 (no DAC)

Plain answers, from the basics to the studies.

Research information, not medical advice.

Often researched with CJC-1295 (no DAC)

FAQ

Questions, answered

  • CJC-1295 without DAC, also called modified GRF 1-29, is a synthetic analog of growth-hormone-releasing hormone (GHRH). It lacks the drug affinity complex (DAC) found in the long-acting version of CJC-1295, giving it a short half-life. Research interest centers on its potential to increase the amount of growth hormone released per pulse while preserving the body's natural pulsatile release pattern, rather than producing sustained elevation.

  • Research describes it as a GHRH analog that acts on GHRH receptors (GHRH-R) in the pituitary, the receptors that govern natural growth hormone pulses. Because it lacks the drug affinity complex, its action is brief rather than prolonged. Research associates this short duration with preserving the body's own pulsatile rhythm of growth hormone secretion, as opposed to the continuous stimulation reported with long-acting analogs.

  • The DAC version is a long-acting GHRH analog. A randomized controlled trial in healthy adults reported prolonged stimulation of growth hormone and insulin-like growth factor I secretion with that form. The no-DAC form, by contrast, has a short half-life and is studied for brief, pulse-level effects. Findings from the DAC trial should not be assumed to apply directly to the no-DAC form, since their durations of action differ substantially.

  • Human safety data specific to CJC-1295 without DAC are limited, and adverse events are not summarized in the cited titles. Recent reviews examine the safety and efficacy of approved and unapproved peptide therapies in musculoskeletal and athletic contexts. GHRH synthetic analogs are also a focus of anti-doping research, with validated detection methods published and glycine-modified secretagogues identified in seized doping material.

  • Research protocols have used 100–300 mcg per administration, 5 days per week (pre-sleep), in 12-week blocks with 4 weeks off, via the subcutaneous route. These figures describe research protocols only and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. CoreX supplies CJC-1295 without DAC for laboratory research use only.

Vial · Pen

Dual-agonist weight research

Tirzepatide · 2 sizes

$139/ 30 mg vial

Vial · Pen

Triple-agonist weight research

GLP-3R · 4 sizes

$119/ 10 mg vial